Effect of high-dose intravenous eletriptan on coronary artery diameter

Cephalalgia

Volumn 24, Issue 7, 2004, Pages 515-521

  Goldstein, J A ^a   Massey, K D ^b   Kirby, S ^c   Gibson, M ^d   Hettiarachchi, J ^b   Rankin, A J ^c   Jackson, N C ^e  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Angiography; Eletriptan; Migraine; Sumatriptan; Vasoconstriction

Indexed keywords

ELETRIPTAN; SUMATRIPTAN SUCCINATE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; HEMODYNAMICS; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN;

ADULT; CONFIDENCE INTERVALS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRROLIDINES; SUMATRIPTAN; TRYPTAMINES; VASOCONSTRICTION;

EID: 2542497227     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2003.00713.x     Document Type: Article

References (26)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346:257-70.
2. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
3. Ottervanger JP, van Witsen TB, Valkenburg HA, Grobbee DE, Stricker BH. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994; 47:305-9.
4. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol 2002; 38:259-69.
5. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side effect potential of current and perspective antimigraine drugs. Circulation 1998; 98:25-30.
6. Connor HE, Feniuk W, Humphrey PP. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 1989; 161:91-4.
7. MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000; 55:1524-30.
8. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 344:985-6.
9. Foster JM, Houghton LA, Whorwell PJ, Morris J. Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Aliment Pharmacol Ther 1999; 13:927-36.
10. Ottervanger JP, Hoorntje JC, Valkenburg HA, Grobbee DE, Stricker BH. Exercise testing in patients with chest pain to sumatriptan. Neth J Med 1998; 53:245-8.
11. Evans RW, Martin V. Expert opinion: assessing cardiac risk prior to use of triptans. Headache 2000; 40:599-602.
12. Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A et al. Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol 1997; 12:3-9.
13. Longmore J, Razzaque Z, Shaw D, Davenport AP, Maguire J, Pickard JD et al. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 1998; 46:577-82.
14. Valentin JP, Bonnafous R, John GW. Contractile responses evoked by dihydroergotamine, naratriptan and sumatriptan in the canine isolated coronary artery. Fundam Clin Pharmacol 1998; 12:152-7.
15. Parsons AA, Raval P, Smith S, Tilford N, King FD, Kaumann AJ et al. Effects of the novel high-affinity 5-HT (1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998; 32:220-4.
16. Muir DF, McCann GP, Swan L, Clark AL, Hillis WS. Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther 1999; 66:85-90.
17. Hood S, Birnie D, Swan L, Murray LS, Whitehouse H, Winter P et al. Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. J Cardiovasc Pharmacol 1999; 34:89-94.
18. Swan L, Hood S, Birnie DH, Muir DF, McCann GP, Hillis WS. The haemodynamic effect of the 5HT1 agonist BMS-180048: a class effect of triptans? Br J Clin Pharmacol 1999; 47:189-94.
19. Hood S, Birnie D, Hillis S. The haemodynamic effects of subcutaneous sumatriptan, a 5HT1-receptor agonist. Br J Clin Pharmacol 1997; 43:327-8.
20. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87:401-5.
21. Macintyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992; 34:541-6.
22. Kop WJ, Krantz DS, Howell RH, Ferguson MA, Papademetriou V, Lu D et al. Effects of mental stress on coronary epicardial vasomotion and flow velocity in coronary artery disease: relationship with hemodynamic stress responses. J Am Coll Cardiol 2001; 37:1359-66.
23. Lacy CR, Contrada RJ, Robbins ML, Tannenbaum AK, Moreyra AE, Chelton S, Kostis JB et al. Coronary vasoconstriction induced by mental stress (simulated public speaking). Am J Cardiol 1995; 75:503-5.
24. Dakak N, Quyyumi AA, Eisenhofer G, Goldstein DS, Cannon RO 3rd. Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. Am J Cardiol 1995; 76:125-30.
25. Priscilla T, Velentgas, Cole A, Mo J, Sikes CR, Walker AM. Triptan use is not associated with increased risk of severe vascular events in migraine patients. Neurology 2003; 60:A254 [Abstract].
26. Hall GC, Brown MM, Mo J, MacRae KD. Migraine, triptan treatment and the risk of cardiovascular disease, stroke and mortality. Neurology 2003; 60:A239-A240 [Abstract].